Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)

Dose–response of an extrafine dry powder inhaler formulation of glycopyrronium bromide: randomized, double-blind, placebo-controlled, dose-ranging study (GlycoNEXT)

Kai M Beeh,1 Aida Emirova,2 Hélène Prunier,2 Debora Santoro,3 Marie Anna Nandeuil2 1Insaf Respiratory Research Institute, Wiesbaden, Germany; 2Global Clinical Development, Chiesi S.A.S, Bois-Colombes, France; 3Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy...

Full description

Bibliographic Details
Main Authors: Beeh KM, Emirova A, Prunier H, Santoro D, Nandeuil MA
Format: Article
Language:English
Published: Dove Medical Press 2018-05-01
Series:International Journal of COPD
Subjects:
Pulmonary disease
chronic obstructive
Muscarinic antagonists
Pulmonary function tests
Dose-response relationship
drug
Metered dose inhalers
Online Access:https://www.dovepress.com/dose-response-of-an-extrafine-dry-powder-inhaler-formulation-of-glycop-peer-reviewed-article-COPD

Internet

https://www.dovepress.com/dose-response-of-an-extrafine-dry-powder-inhaler-formulation-of-glycop-peer-reviewed-article-COPD

Similar Items